New Medicines

Ulcerative colitis


New molecular entity

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Jul 19Jun 19: PIII trial ELEVATE UC 52 starts (NCT 03945188); this is a one-year randomized (2:1) placebo-controlled trial to assess the efficacy and safety of etrasimod 2 mg once-daily moderate- severe active ulcerative colitis with an endoscopic score and rectal bleeding. The estimated primary completion date is Nov 2021 [5].


Selectively targets the sphingosine 1 phosphate type 1 (S1p1) receptor to reduce circulating lymphocytes by disrupting lymphocyte migration from the lymphoid organs into the blood. Fewer circulating lymphocytes are available to cause tissue damage.[2]
Ulcerative colitis is the most common type of inflammatory disease of the bowel. It has an incidence in the UK of approximately 10 per 100,000 people annually and a prevalence of approximately 240 per 100,000. Ulcerative colitis can develop at any age but peak incidence is between the ages of 15 and 25 years, with a second, smaller peak between 55 and 65 years [1].
Ulcerative colitis